how many people take glp 1 drugs GLP-1 trends 2025: real-world data, patient outcomes & future therapies The risk too many people

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

Discover cost-effective, personalized weight loss solutions

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes

Clinicians may consider closer INR monitoring following GLP-1 RA initiation

A pattern of musculoskeletal injuries spurred researchers to conduct a study on whether using the popular weight-loss and diabetes drugs increased a persons risk of other health conditions.

Acting as a natural appetite suppressant, this formula works as both a GLP-1 support and metabolic booster, helping regulate hunger signals, boost metabolism and naturally promote fat burn, making a perfect complement to mindful eating and an active lifestyle